IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Fixed date of 39th Annual General Meeting of the Company and Book Closure of Register of Members
IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.5 pts more than Nifty Microcap 250 and 7.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
IOL Chemicals reported standalone revenue of Rs 2,319 crore for FY2026, up 11.5% from Rs 2,079 crore in FY2025. PAT grew 36.4% to Rs 137.7 crore from Rs 101 crore, beating the 25% threshold. EBITDA margin expanded from 10.4% to 11.5% year-on-year. The company received an unmodified (clean) audit opinion from its statutory auditors with no going concern issues. Exceptional items of Rs 11.21 crore were recorded due to one-time employee restructuring costs under new Labour Codes. The Board also approved two capacity expansions: a new Triacetin manufacturing facility (6,000 MTPA) at Rs 16.88 crore and Pantoprazole capacity increase from 240 to 276 MTPA at Rs 5.87 crore, both funded through internal accruals. The 39th AGM is scheduled for 2nd September 2026.
Strong profit growth and margin expansion signal operational efficiency gains. The clean audit and expansion plans into new products like Triacetin (used in food, pharma, cosmetics) indicate healthy business prospects, which could be positive for the stock.